Aurobindo receives FDA nod for generic Pennsaid
Diclofenac sodium topical solution is indicated for the treatment of osteoarthritis.
Aurobindo Pharma’s Aurolife Pharma, has received the Food and Drug Administration’s permission for diclofenac sodium topical solution, a generic of Horizon’s Pennsaid.
Diclofenac sodium topical solution, indicated for the treatment of osteoarthritis, is expected to launch in the first quarter of 2024.
[Read more: Aurobindo receives FDA approval for 3 generics]
Diclofenac sodium topical solution had a market value of roughly $487 million for the 12 months ending December 2022, according to IQVIA.
“This is the first ANDA to be approved out of the Aurolife Unit-II, North Carolina, USA, used for manufacturing topical products,” Aurobindo said.